OA01.06 First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study
Yi-Kan Cheng(Jilin Province Tumor Hospital), Yong Song(Nanjing General Hospital of Nanjing Military Command), Yao Zhao(Chengdu University of Technology), Jun Zhao(Peking University), Mingu Kang(Seoul National University), Dabing Huang(Tianjin Medical University Cancer Institute and Hospital), Wenling Zheng(First Affiliated Hospital of Xi'an Jiaotong University), Yan Yu(Army Medical University), Xun Li(Western Sydney University), Ying Zhang(Sun Yat-sen University), Chang Chen(China Academy of Chinese Medical Sciences), Yun Fan(Zhejiang Cancer Hospital), Peihong Zhang(Tongji University), Shiang Jiin Leaw(State Key Laboratory of Oncogene and Related Genes), Zheng Wang(Qilu University of Technology), T J Qin, Ning Yang(First Affiliated Hospital of Hebei Medical University), Dingyong Zhong(Sun Yat-sen University)
Cited by 23
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
|Signal Transduction and Targeted Therapy|2022|988
Traditional Chinese Medicine in Cancer Care: A Review of Controlled Clinical Studies Published in Chinese
|PLoS ONE|2013|607